| Holding(s) in Company | 12-Feb-2026 | 11:49 | RNS |
| Holding(s) in Company | 06-Feb-2026 | 10:24 | RNS |
| Exercise of Options & TVR | 27-Jan-2026 | 17:42 | RNS |
| Trading Update and Notice of Results | 21-Jan-2026 | 07:00 | RNS |
| Issue of Share Options | 12-Jan-2026 | 17:13 | RNS |
| Notification of Major Holdings | 08-Dec-2025 | 14:34 | RNS |
| Result of AGM - Board Appointment | 27-Nov-2025 | 13:59 | RNS |
| Exercise of Options & PDMR Dealings | 14-Nov-2025 | 08:38 | RNS |
| Adaptix receives FDA 510(K) clearance | 10-Nov-2025 | 07:00 | RNS |
| Exercise of Options & Total Voting Rights | 01-Oct-2025 | 16:52 | RNS |
| Holding(s) in Company | 01-Oct-2025 | 15:32 | RNS |
| Appointment of Medical Division CEO | 29-Sep-2025 | 07:00 | RNS |
| Preliminary results for the year ended 31 May 2025 | 24-Sep-2025 | 07:00 | RNS |
| Holding(s) in Company | 11-Sep-2025 | 08:00 | RNS |
| Hayward Tyler Secures $16m Nuclear Contracts | 02-Sep-2025 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 565.00p |
| Change Today | -10.00p |
| % Change | -1.74 % |
| 52 Week High | 600.00 |
| 52 Week Low | 310.00 |
| Volume | 36,436 |
| Shares Issued | 33.27m |
| Market Cap | £187.97m |
| Beta | 0.21 |
| RiskGrade | 130 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 0 |
| Buy | 1 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 1 |

| Latest | Previous | |
|---|---|---|
| Final | Interim | |
| Ex-Div | 06-Nov-25 | 29-May-25 |
| Paid | 19-Dec-25 | 27-Jun-25 |
| Amount | 3.00p | 1.90p |
| Time | Volume / Share Price |
| 15:43 | 5,000 @ 567.00p |
| 16:21 | 634 @ 566.58p |
| 16:07 | 1,000 @ 566.75p |
| 14:22 | 7,500 @ 563.55p |
| 15:01 | 655 @ 560.00p |
| Finance Director | Stephen King |
| Chair | Roger Steven McDowell |
| CEO | Stephen McQuillan |
You are here: research